Gene Therapy of Ovarian Cancer—State-of-the-Art and Future Perspectives

Diagnosis and Management of Ovarian Disorders, Second Edition

Volumn , Issue , 2003, Pages 277-304

  Kieback, Dirk G ^a   Hasenburg, Annette ^b   Runnebaum, Ingo B ^b   Tong, Xiao W ^c   Fischer, Dagmar C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

^c TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876446477     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012053642-9/50026-0     Document Type: Chapter

References (362)

1. I.B. Runnebaum and E. Stickeler (2001) Epidemiological and molecular aspects of ovarian cancer risk. J. Cancer. Res. Clin. Oncol. 127 73-79.
2. T. Bjørge, A. Engeland, K. Sundfor and C.G. Tropé (1998) Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975–94 and treated at the Norwegian Radium Hospital. Acta Obstet. Gynecol. Scand. 77 777-781.
3. T. Bjørge, A. Engeland, S. Hansen and C.G. Tropé (1998) Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int. J. Cancer 75 663-670.
4. J. Dauplat, G. Le Bouedec, C. Pomel and C. Scherer (2000) Cytoreductive surgery for advanced stages of ovarian cancer. Semin. Surg. Oncol. 19 42-48.
5. F.G. Lawton (1995) Secondary debulking in ovarian cancer: Is it all in the timing? Curr. Opin. Obstet. Gynecol. 7 1-3.
6. T. Riman, I. Persson and S. Nilsson (1997) Hormonal aspects of epithelial ovarian cancer: Review of epidemiological evidence. Clin. Endocrinol. 49 695-707.
7. G. Michel, P. De Iaco, D. Castaigne, M.J. El-Hassan, R. Lobreglio, C. Lhomme, A. Rey and P. Duvillard (1997) Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur. J. Genaecol. Oncol. 18 9-15.
8. S.M. Eisenkop, R.L. Friedman and H.J. Wang (1998) Complete cytoreductive surgery is feasible and maximizes, survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol. Oncol. 69 103-108.
9. L.L. McCluskey and L. Dubeau (1997) Biology of ovarian cancer. Curr. Opin. Oncol. 9 465-470.
10. L. Dubeau (1999) The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: Does the emperor have no clothes? Gynecol. Oncol. 72 437-442.
11. N. Auersperg, A.S. Wong, K.C. Choi, S.K. Kang and P.C. Leung (2001) Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocr. Rev. 22 255-288.
12. C.C. Van Niekerk, F.C. Ramaekers, A.G. Hanselaar, J. Aldeweireldt and L.G. Poels (1993) Changes in expression of differentiation markers between normal ovarian cells and derived tumors. Am. J. Pathol. 142 157-177.
13. A. Al-Hendy, A.M. Magliocco, T. Al-Tweigeri, G. Braileanu, N. Crellin, H. Li, T. Strong, D. Curiel and P.J. Chedrese (2000) Ovarian cancer gene therapy: Repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model. Am. J. Obstet. Gynecol. 182 553-559.
14. Y. Yamaguchi, I. Takashima, J. Hihara, K. Ohta, K. Shimizu, K. Minami, K. Yoshida and T. Toge (2000) Co-transduction of herpes simplex virus thymidine kinase gene and human interleukin-2 gene into mouse ovarian cancer cell line, OVHM. Int. J. Mol. Med. 6 185-190.
15. C.D. Hough, C.A. Sherman-Baust, E.S. Pizer, F.J. Montz, D.D. Im, N.B. Rosenshein, K.R. Cho, G.J. Riggins and P.J. Morin (2000) Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60 6281-6287.
16. C.D. Hough, K.R. Cho, A.B. Zonderman, D.R. Schwartz and P.J. Morin (2001) Coordinately upregulated genes in ovarian Cancer. Cancer Res. 61 3869-3876.
17. J.B. Welsh, P.P. Zarrinkar, L.M. Sapinoso, S.G. Kern, C.A. Behling, B.J. Monk, D.J. Lockhart, R.A. Burger and G.M. Hampton (2001) Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA 98 1176-1181.
18. D.M. Parkin, O. Pisani and J. Ferlay (1993) Estimates of the world-wide incidence of eighteen major cancers in 1985. Int. J. Cancer. 54 594-606.
19. S.M. Rowe, S.J. Coughlan, N.J. McKenna, E. Garrett, D.G. Kieback, D.N. Carney and D.R. Headon (1995) Ovarian carcinoma associated TaqI restriction fragment length polymorphism in Intron G of the progesterone receptor gene is due to an alu sequence ins. Cancer Res. 55 2743-2745.
20. I.B. Runnebaum, S. Wang-Gohrke, D. Vesprini, R. Kreienberg, H. Lynch, R. Moslehi, P. Ghadirian, B. Weber, A.K. Godwin, H. Risch, J. Garber, C. Lerman, O.L. Olipade, W.D. Foulkes, B. Karlan, E. Warner, B. Rossen, T. Rebbeck, P. Tonin, M.-P. Dubé, D.G. Kieback and S.A. Narod (2001) Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics 11 1-4.
21. B. Aunoble, R. Sanches, E. Didier and Y.J. Bignon (2000) Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int. J. Oncol. 16 567-576.
22. M. Hollstein, K. Rice, M.S. Greenblatt, T. Soussi, R. Fuchs, T. Sorlie, E. Hovig, B. Smith-Sorensen, R. Montesano and C.C. Harris (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22 3551-3555.
23. M. Weller (1998) Predicting response to cancer chemotherapy: The role of p53. Cell Tissue Res. 292 435-445.
24. K. Somasudaram and W.S. El-Deiry (2000) Tumor suppressor p53: Regulation and function. Front. Biosci. 5 d424-d437.
25. G.C. Rodriguez, A. Berchuck, R.S. Whitaker, D. Schlossman, D.L. Clarke-Pearson and R.C. Bast Jr. (1991) Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am. J. Obstet. Gynecol. 164 745-750.
26. J.V. Ilekis, J.P. Connor, G.S. Prins, K. Ferrer, C. Niederberger and B. Scoccia (1997) Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol. Oncol. 66 250-254.
27. X.W. Tong, D.G. Kieback, R. Ramesh and S.M. Freeman (1999) Molecular aspects of ovarian cancer. Hematol. Oncol. Clin. N. Am. 13 109-133.
28. T. Ross d.T., U. Scherf, M.B. Eisen, C.M. Perou, C. Rees, P. Spellman, V. Iyer, S.S. Jeffrey, M. Van de Rijn, M. Waltham, A. Pergamenschikov, J.C. Lee, D. Lashkari, D. Shalon, T.G. Myers, J.N. Weinstein, D. Botstein and P.O. Brown (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24 227-235.
29. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, K.Y. Look, D.L. Clarke-Pearson and M. Davidson (1996) Cyclophosphamide and cisplatin compared with paclitaxed and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 1-6.
30. A. Di Cristofano and P.P. Pandolfi (2000) The multiple roles of PTEN in tumor suppression. Cell 100 387-390.
31. C. Tsatsanis and D.A. Spandidos (2000) The role of oncogenic kinases in human cancer. Int. J. Mol. Med. 5 583-590.
32. H.L. Weiner and D. Zagzag (2000) Growth factor receptor tyrosine kinases: Cell adhesion kinase family suggests a novel signaling mechanism in cancer. Cancer Invest. 18 544-554.
33. L.N. Klapper, M.H. Kirschbaum, M. Sela and Y. Yarden (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77 25-79.
34. D. Hanahan and R.A. Weinberg (2000) The hallmarks of cancer. Cell 100 57-70.
35. M.O. Hengartner (2000) The biochemistry of apoptosis. Nature 407 770-776.
36. T. Hunter (2000) Signaling—2000 and beyond. Cell 100 113-127.
37. R.I. Mahato, L.C. Smith and A. Rolland (1999) Pharmaceutical perspectives of nonviral gene therapy. Adv. Genet. 41 95-156.
38. W.F. Anderson (1998) Human gene therapy. Nature 392 25-30.
39. W. Walther and U. Stein (2000) Viral vectors for gene transfer: A review of their use in the treatment of human diseases. Drugs 60 249-271.
40. A.G. Schatzlein (2001) Non-viral vectors in cancer gene therapy: Principles and progress. Anticancer Drugs 12 275-304.
41. R.I. Garver Jr., K.T. Goldsmith, B. Rodu, P.C. Hu, E.J. Sorscher and D.T. Curiel (1994) Strategy for achieving selective killing of carcinomas. Gene Ther. 1 46-50.
42. W. Walther and U. Stein (1999) Therapeutic genes for cancer gene therapy. Mol. Biotechnol. 13 21-28.
43. P. Anklesaria (2000) Gene therapy: A molecular approach to cancer treatment. Curr. Opin. Mol. Ther. 2 426-432.
44. R.G. Vile, S.J. Russell and N.R. Lemoine (2000) Cancer gene therapy: Hard lessons and new courses. Gene Ther. 7 2-8.
45. Y. Oshima, T. Sakamoto, I. Yamanaka, T. Nishi, T. Ishibashi and H. Inomata (1998) Targeted gene transfer to corneal endothelium in vivo by electric pulse. Gene Ther. 5 1347-1354.
46. D. Sawamura, S. Ina, K. Itai, X. Meng, A. Kon, K. Tamai, K. Hanada and I. Hashimoto (1999) In vivo gene introduction into keratinocytes using jet injection. Gene Ther. 6 1785-1787.
47. K.M. Hui and T.F. Chia (1997) Eradication of tumor growth via biolistic transformation with allogeneic MHC genes. Gene Ther. 4 762-767.
48. M.E. Barry, D. Pinto-Gonzalez, F.M. Orson, G.J. McKenzie, G.R. Petry and M.A. Barry (1999) Role of endogenous endonu-cleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection. Hum Gene Ther 10 2461-2480.
49. D. Luo and W.M. Saltzman (2000) Synthetic DNA delivery systems. Nat. Biotechnol. 18 33-37.
50. D.J. Maron, E.A. Choi and F.R. Spitz (2001) Gene therapy of metastatic disease: Progress and prospects. Surg. Oncol. Clin. N. Am. 10 449-460.
51. F.M. Muggia (2001) Liposomal encapsulated anthracyclines: New therapeutic horizons. Curr. Oncol. Rep. 3 156-162.
52. A. Kikuchi, Y. Aoki, S. Sugaya, T. Serikawa, K. Takakuwa, K. Tanaka, N. Suzuki and H. Kikuchi (1999) Development of novel cationic liposomes for efficient gene transfer into peritoneal disseminated tumor. Hum Gene Ther. 10 947-955.
53. X. Xing, S. Zhang, J.Y. Chang, S.D. Tucker, H. Chen, L. Huang and M.C. Hung (1998) Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. Gene Ther. 5 1538-1544.
54. N.T. Ueno, W. Xia, S.D. Tucker, S. Zhang, G. Lopez-Berestein, L. Huang and M.C. Hung (1999) Issues in the development of gene therapy: Preclinical experiments in E1A gene delivery. Oncol. Rep. 6 257-262.
55. G.N. Hortobagyi, M.C. Hung and G.A. Lopez-Berestein (1998) Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overex-presses HER-2/neu or epithelial ovarian cancer. Hum Gene Ther. 9 1775-1798.
56. W.H. Günzburg and B. Salmons (1996) Development of retroviral vectors as safe, targeted gene delivery systems. J. Mol. Med. 74 171-182.
57. D. Markowitz, S. Goff and A. Bank (1988) A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J. Virol. 62 1120-1124.
58. D.G. Miller and A.D. Miller (1994) A family of retroviruses that utilize related phosphate transporters for cell entry. J. Virol. 68 8270-8276.
59. E. Galanis, R. Vile and S.J. Russell (2001) Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors. Crit. Rev. Oncol. Hematol. 38 177-192.
60. D.G. Miller, M.A. Adam and A.D. Miller (1990) Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10 4239-4242.
61. J.R. McLachlin, K. Cornetta, M.A. Eglitis and W.F. Anderson (1990) Retroviral-mediated gene transfer. Prog. Nucleic Acid Res. Mol. Biol. 38 91-135.
62. S.F. Yu, T. von Ruden, P.W. Kantoff, C. Garber, M. Seiberg, U. Ruther, W.F. Anderson, E.F. Wagner and E. Bilboa (1986) Selfinactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA. 83 3194-3198.
63. H. Ishii-Morita, R. Agbaria, C.A. Mullen, H. Hirano, D.A. Koeplin, Z. Ram, E.H. Oldfield, D.G. Johns and R.M. Blaese (1997) Mechanism of ‘bystander effect’ killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 4 244-251.
64. J.C. Burns, T. Friedmann, W. Driever, M. Burrascano and J.K. Yee (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA. 90 8033-8037.
65. T. Friedman and J.K. Yee (1995) Pseudotyped retroviral vectors for studies of human gene therapy. Nat. Med. 1 275-277.
66. J. Reiser, G. Harmison, S. Kluepfel-Stahl, R.O. Brady, S. Karlsson and M. Schubert (1996) Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. USA 93 15266-15271.
67. N. Kasahara, A.M. Dozy and Y.W. Kan (1994) Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266 1373-1376.
68. M. Marin, D. Noel, S. Valsesia-Wittman, F. Brockly, M. Etienne-Julan, S. Russell, F.L. Cosset and M. Piechaczyk (1996) Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J. Virol. 70 2957-2962.
69. N.V. Somia, M. Zoppe and I.M. Verma (1995) Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery. Proc. Natl. Acad. Sci. USA 92 7570-7574.
70. B.S. Schnierle and B. Groner (1996) Retroviral targeted delivery. Gene. Ther. 3 1069-1073.
71. B.S. Schnierle, D. Moritz, M. Jeschke and B. Groner (1996) Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles. Gene Ther. 3 334-342.
72. A. Jiang, T.H. Chu, F. Nocken, K. Cichutek and R. Dornburg (1998) Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies. J. Virol. 72 10148-10156.
73. S. Snitkovsky and J.A. Young (1998) Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein. Proc. Natl. Acad. Sci. USA 95 7063-7068.
74. F.L. Cosset and S.J. Russell (1996) Targeting retrovirus entry. Gene Ther. 3 946-956.
75. D. Ott and A. Rein (1992) Basis for receptor specificity of nonecotropic murine leukemia virus surface glycoprotein gp70SU. J. Virol. 66 4632-4638.
76. R.A. Morgan, O. Nussbaum, D.D. Muenchau, L. Shu, L. Couture and W.F. Anderson (1993) Analysis of the functional and host rangedetermining regions of the murine ectropic and amphotropic retrovirus envelope proteins. J. Virol. 67 4712-4721.
77. J.L. Battini, J.M. Heard and O. Danos (1992) Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses. J. Virol. 66 1468-1475.
78. S.J. Russell, R.E. Hawkins and G. Winter (1993) Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 21 1081-1085.
79. B. Salmons and W.H. Gunzburg (1993) Targeting of retroviral vectors for gene therapy. Hum. Gene Ther. 4 129-141.
80. R.P. Rother, S.P. Squinto, J.M. Mason and S.A. Rollins (1995) Protection of retroviral vector particles in human blood through complement inhibition. Hum. Gene Ther. 6 429-435.
81. D.L. Tait, P.S. Obermiller, S. Redlin-Frazier, R.A. Jensen, P. Welcsh, J. Dann, M.C. King, D.H. Johnson and J.T. Holt (1997) A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin. Cancer Res. 3 1959-1968.
82. S.K. Ayesh, Y. Azar, I.I. Barghouti, J.M. Ruedi, B.M. Babior and Y. Matzner (1995) Purificition and characterization of a C5ainactivating enzyme from human peritoneal fluid. Blood 85 3503-3509.
83. S.M. Freeman, C. McCune, W. Robinson, C.N. Abboud, G.N. Abraham, C. Angel and A. Marrogi (1995) The treatment of ovarian cancer with a gene modified cancer vaccine: A phase I study. Hum. Gene Ther. 6 927-939.
84. C.J. Link Jr., D. Moorman, T. Seregina, J.P. Levy and K.J. Schabold (1996) A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum. Gene Ther. 7 1161-1179.
85. C.R. Logg, C.K. Tai, A. Logg, W.F. Anderson and N. Kasahara (2001) A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum. Gene Ther. 12 921-932.
86. V.N. Kim, K. Mitrophanous, S.M. Kingsman and A.J. Kingsman (1998) Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72 811-816.
87. L. Naldini, U. Blomer, P. Gallay, D. Ory, R. Mulligan, F.H. Gage, I.M. Verma and D. Trono (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 263-267.
88. R. Zufferey, D. Nagy, R.J. Mandel, L. Naldini and D. Trono (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15 871-875.
89. D. Schnurr and M.E. Dondero (1993) Two new candidate adenovirus serotypes. Intervirology 36 79-83.
90. P.W. Roelvink, A. Lizonova, J.G. Lee, Y. Li, J.M. Bergelson, R.W. Finberg, D.E. Brough, I. Kovesdi and T.J. Wickham (1998) The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 72 7909-7915.
91. A. Bailey and V. Mautner (1994) Phylogenetic relationships among adenovirus serotypes. Virology 205 438-452.
92. G. Wadell (2000) Adenoviruses. A.J. Zuckerman, J.E. Banatvala, J.R. Pattison (Eds) Principles and Practice of Clinical Virology 4th edition New York: John Wiley & Sons 307-327. Chapter 8
93. J. Chroboczek, R.W.H. Ruigrok and S. Cusack (1995) Adenovirus fiber. Curr. Top. Microbiol. Immunol. 199 163-200.
94. M. Perricaudet and L.D. Stratford-Perricaudet (1995) Adenovirusmediated in-vivo gene therapy. J.-M.H. Vos (Eds) Viruses in Human Gene Therapy Durham, NC: Academic Press 1-32.
95. J.M. Bergelson, J.A. Cunnigham, G. Droguett, E.A. Kurt-Jones, A. Krithivas, J.S. Hong, M.S. Horwitz, R.L. Crowell and R.W. Finberg (1997) Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275 1320-1323.
96. S.S. Hong, L. Karayan, J. Tournier, D.T. Curiel and P.A. Boulanger (1997) Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J. 16 2294-2306.
97. G.R. Nemerow, D.A. Cheresh and T.J. Wickham (1994) Adenovirus entry into host cells. A role for αv integrins. Trends Cell Biol. 4 52-56.
98. T.J. Wickham, P. Mathias, D.A. Cheresh and G.R. Nemerow (1993) Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73 309-319.
99. T.J. Vickham, E.J. Filardo, D.A. Cheresh and G.R. Nemerow (1994) Integrin αvβ5 selectively promotes adenovirus mediated cell membrane permeabilization. J. Cell Biol. 127 257-264.
100. C. Hidaka, E. Milano, P.L. Leopold, J.M. Bergelson, N.R. Hackett, R.W. Finberg, T.J. Wickham, I. Kovesdi, P. Roelvink and R.G. Crystal (1999) CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J. Clin. Invest. 103 579-587.
101. K.N. Wills, D.C. Maneval, P. Menzel, M.P. Harris, S. Sutjipto, M.T. Vaillancourt, W.M. Huang, D.E. Johnson, S.C. Anderson, S.F. Wen, et al. (1994) Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther. 5 1079-1088.
102. U.F. Greber, M. Willetts, P. Webster and A. Helenius (1993) Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75 477-486.
103. U.F. Greber, I. Singh and A. Helenius (1994) Mechanisms of virus uncoating. Trends Microbiol. 2 52-56.
104. U.F. Greber, P. Webster, J. Weber and A. Helenius (1996) The role of the adenovirus protease in virus entry into the cells. EMBO J. 15 1766-1777.
105. U.F. Greber, M. Suomalainen, R.P. Stidwill, K. Boucke, M.W. Ebersold and A. Helenius (1997) The role of the nuclear pore complex in adenovirus DNA entry. EMBO J. 16 5998-6007.
106. M. Cotton and J.M. Weber (1995) The adenovirus protease is required for virus entry into host cells. Virology 213 494-502.
107. G.R. Whittaker and A. Helenius (1998) Nuclear import and export of viruses and virus genomes. Virology 246 1-23.
108. S. Huang, R.I. Endo and G.R. Nemerow (1995) Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J. Virol. 69 2257-2263.
109. S. Hemmi, R. Geertsen, A. Mezzacasa, I. Peter and R. Dummer (1998) The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum. Gene Ther. 9 2363-2373.
110. G. Teoh, L. Chen, M. Urashima, Y.T. Tai, L.A. Celi, D. Chen, D. Chauhan, A. Ogata, R.W. Finberg, I.J. Webb, D.W. Kufe and K.C. Anderson (1998) Adenovirus vector-based purging of multiple myeloma cells. Blood 92 4591-4601.
111. T. Hautala, T. Grunst, A. Fabrega, P. Freimuth and M.J. Welsh (1998) An interaction between penton base and alpha v integrins plays a minimal role in adenovirus-mediated gene transfer to hepatocytes in vitro and in vivo. Gene Ther. 5 1259-1264.
112. Y. Li, R.C. Pong, J.M. Bergelson, M.C. Hall, A.I. Sagalowsky, C.P. Tseng, Z. Wang and J.T. Hsieh (1999) Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res. 59 325-330.
113. R.J. Pickles, D. McCarty, H. Matsui, P.J. Hart, S.H. Randell and R.C. Boucher (1998) Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J. Virol. 72 6014-6023.
114. J. Nalbantoglu, G. Pari, G. Karpati and P.C. Holland (1999) Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum. Gene Ther. 10 1009-1019.
115. A. Brüning, T. Kohler, S. Quist, S. Wang-Gohrke, V.J. Moebus, R. Kreienberg and I.B. Runnebaum (2001) Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3. Hum. Gene Ther. 12 391-399.
116. Z. You, D.C. Fischer, X. Tong, A. Hasenburg, E. Aguilar-Cordova and D.G. Kieback (2001) Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression. Cancer Gene Ther. 8 168-175.
117. M.A. Morsy and C.T. Caskey (1999) Expanded-capacity adenoviral vectors—the helper-dependent vectors. Mol. Med. Today 5 18-24.
118. P. Yeh and M. Perricaudet (1997) Advances in adenoviral vectors: From genetic engineering to their biology. FASEB J. 11 615-623.
119. T. Shenk (1996) Adenoviridiae: The viruses and their replication. K.D. Fields, D.M. Knipe, P.M. Howley, et al., (Eds) 3rd edition Viroblogy vol. 2 Philadelphia: Raven Publishers 2111-2148. Chapter 67
120. S.T. Bayley and J.S. Mamryk (1994) Adenovirus E1A proteins and transformation. Int. J. Oncol. 5 525.
121. J. Shisler, P. Duerksen-Hughes, T.M. Hermiston, W.S. Wold and L.R. Gooding (1996) Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p 105-Rb and induction of DNA synthesis. J. Virol. 70 68-77.
122. F.L. Graham, J. Smiley, W.C. Russell and R. Nairn (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36 59-74.
123. S.M. Frisch (2001) Tumor suppression activity of adenovirus E1a protein: Anoikis and the epithelial phenotype. Adv. Cancer Res. 39-49.
124. T. Reynolds, D. Alberts, D. Gershenson, L. Gleich, B. Glisson, E. Hanna, L. Huang, M.C. Hung, D. Kenady, N. Ueno, D. Villaret and G. Yoo (2000) Activity of E1a in human clinical trials. Proc. Am. Soc. Clin. Oncol. pp. abstr. 1809
125. G.H. Yoo, M.C. Hung, G. Lopez-Berestein, S. LaFollette, J.F. Ensley, M. Carey, E. Batson, T.C. Reynolds and J.L. Murray (2001) Phase I trial of intratumoral liposome E1a gene therapy in patients with recurrent breast and head and neck cancer. Clin. Cancer Res. 7 1237-1245.
126. R.Y. Zang, D.R. Shi, H.J. Lu, S.M. Cai, D.R. Lu, Y.J. Zhang and H.L. Qin (2001) Adenovirus 5 E1a-mediated gene therapy for human ovarian cancer cells in vitro and in vivo. Int. J. gynecol. Cancer 11 18-23.
127. M.E. Martin and A.J. Berk (1998) Adenovirus E1B 55K represses p53 activation in vitro. J. Virol. 72 3146-3154.
128. J.M. Adams and S. Cory (1998) The Bcl-2 protein family: Arbiters of cell survival. Science 281 1322-1326.
129. W.S.M. Wold, K. Doronin, K. Toth, M. Kuppuswamy, D.L. Lichtenstein and A.E. Tollefson (1999) Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic. Curr. Opin. Immunol. 11 380-386.
130. J.N. Fredman and J.A. Engler (1993) Adenovirus precursor to terminal protein interacts with the nuclear matrix in vivo and in vitro. J. Virol. 67 3384-3395.
131. J. Schaack, W.Y. Ho, P. Freimuth and T. Shenk (1990) Adenovirus terminal protein mediates both nuclear matrix association and efficient transcription of adenovirus DNA. Genes Dev. 4 1197-1208.
132. J.L. Williams, J. Garcia, D. Harrich, L. Pearson, F. Wu and R. Gaynor (1990) Lymphoid specific gene expression of the adenovirus early region 3 promoter is mediated by NF-kappa B binding motifs. EMBO J. 9 4435-4442.
133. A.E. Tollefson, A. Scaria, T.W. Hermiston, J.S. Ryerse, L.J. Wold and W.S. Wold (1996) The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70 2296-2306.
134. T.W. Hermiston, R.A. Tripp, T. Sparer, L.R. Gooding and W.S. Wold (1993) Deletion mutation analysis of the adenovirus type 2 E3-gp 19K protein: Identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes. J. Virol. 67 5289-5298.
135. T. Dimitrov, P. Krajcsi, T.W. Hermiston, A.E. Tollefson, M. Hannink and W.S. Wold (1997) Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes. J. Virol. 71 2830-2837.
136. V. Descamps, M.T. Duffour, M.C. Mathieu, N. Fernandez, L. Cordier, M.A. Abina, E. Kremer, M. Perricaudet and H. Haddada (1996) Strategies for cancer gene therapy using adenoviral vectors. J. Mole. Med. 74 183-189.
137. K.M. Hehir, D. Armentano, L.M. Cardoza, T.L. Choquette, P.B. Berthelette, G.A. White, L.A. Couture, M.B. Everton, J. Keegan, J.M. Martin, D.A. Pratt, M.P. Smith, A.E. Smith and S.C. Wadsworth (1996) Molecular characterization of replicationcompetent variants of adenovirus vectors and genome modifications to prevent their occurrence. J. Virol. 70 8459-8467.
138. J.L. Imler, C. Chartier, D. Dreyer, A. Dieterle, M. Sainte-Marie, T. Faure, A. Pavirani and M. Mehtali (1996) Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. Gene Ther. 3 75-84.
139. A.J. Bett, L. Prevec and F.L. Graham (1993) Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67 5911-5921.
140. M. Ali, N.R. Lemoine and C.J. Ring (1994) the use of DNA viruses as vectors for gene therapy. Gene Ther. 1 367-384.
141. M. Lusky, M. Christ, K. Rittner, A. Dieterle, D. Dreyer, B. Mourot, M. Schultz, F. Stoeckel, A. pavirani and M. Mehtali (1998) In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol. 72 2022-2032.
142. I. Kovesdi, D.E. Brough, J.T. Bruder and T.J. Wickham (1997) Adenoviral vectors for gene transfer. Curr. Opin. Biotechnol 8 583-589.
143. K.J. Fisher, H. Choi, J. Burda, S.J. Chen and J.M. Wilson (1996) Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217 11-22.
144. S. Kochanek, P.R. Clemens, K. Mitani, H.-H. Chen, S. Chan and C.T. Caskey (1996) A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc. Natl. Acad. Sci. USA 93 5731-5736.
145. S.M. Freeman, C.N. Abboud, K.A. Whartenby, C.H. Packman, D.S. Koeplin, F.L. Moolten and G.N. Abraham (1993) The “bystander effect”: Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53 5274-5283.
146. A.A. Elshami, A. Saavedra, H. Zhang, J.C. Kucharczuk, D.C. Spray, G.I. Fishman, K.M. Amin, L.R. Kaiser and S.M. Albelda (1996) Gap junctions play a role in the “bystander effect” of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 3 85-92.
147. X.W. Tong, A. Block, S.H. Chen, S.L. Woo and D.G. Kieback (1996) Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir. Anticancer Res. 16 1611-1617.
148. N.P. Rizk, M.Y. Chang, C.E. Kouri, P. Seth, L.R. Kaiser, S.M. Albelda and K.A. Amin (1999) The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer. Cancer Tene Ther. 6 291-301.
149. D.H. Kirn (2000) Replication-selective microbiological agents: Fighting cancer with targeted germ warfare. J. Clin. Invest. 105 837-839.
150. C. Heise and D.H. Kirn (2000) Replication-selective adenoviruses as oncolytic agents. J. Clin. Invest. 105 847-851.
151. S. Agha-Mohammadi and M.T. Lotze (2000) Immunomodulation of cancer: Potential use of selectively replicating agents. J. Clin. Invest. 105 1173-1176.
152. T. Hermiston (2000) Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer. J. Clin. Invest. 105 1169-1172.
153. R. Rodriguez, E.R. Schuur, H.Y. Lim, G.A. Henderson, J.W. Simons and D.R. Henderson (1997) Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57 2559-2563.
154. P.L. Hallenbeck, Y.N. Chang, C. Hay, D. Golightly, D. Stewart, J. Lin, S. Phipps and Y.L. Chiang (1999) A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10 1721-1733.
155. K. Doronin, M. Kuppuswamy, K. Toth, A.E. Tollefson, P. Krajcsi, V. Krougliak and W.S. Wold (2001) Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J. Virol. 75 3314-3324.
156. J.R. Bischoff, D.H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J.A. Nye, A. Sampson-Johannes, A. Fattaey and F. McCormick (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 373-376.
157. C. Heise, A. Sampson-Johannes, A. Williams, F. McCormick, D.D. von Hoff and D.H. Kirn (1997) ONYX-015, an E1B geneattenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3 639-645.
158. I. Ganly, S.G. Eckhardt, G.I. Rodriguez, D.S. Soutar, R. Otto, A.G. Robertson, O. Park, M.L. Gulley, C. Heise, D.D. Von Hoff and S.B. Kaye (2000) A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6 798-806.
159. F.R. Khuri, J. Neumunaitis, I. Ganly, J. Arseneau, I.F. Tannock, L. Romel, M. Gore, J. Ironside, R.H. MacDougall, C. Heise, B. Randlev, A.M. Gillenwater, P. Bruso, S.B. Kaye, W.K. Hong and D.H. Kirn (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cis-platin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6 879-885.
160. P.A. Vasey, M. Seiden, V. O'Neill, S. Campo, S. Johnston, J. Davis, D. Kirn, S.B. Kaye and L.N. Shulman (2000) Phase I trial of intraperitoneal ONYX-015 adenovirus in patients with recurrent ovarian cancer. Proc. ASCO 2000 pp. Abstract #1512.
161. C.J. Springer and I. Niculescu-Duvaz (2000) Prodrug-activating systems in suicide gene therapy. J. Clin. Invest. 105 1161-1167.
162. S.O. Freytag, R. Rogulski, D.L. Paielli, J.D. Gilbert and J.H. Kim (1998) A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9 1323-1333.
163. O. Wildner, J.C. Morris, N.N. Vahanian, H. Ford Jr., W.J. Ramsey and R.M. Blaese (1999) Adenoviral vectors capable of replication improve the efficacy of HSVtk/GVC suicide gene therapy of cancer. Gene Ther. 6 57-62.
164. O. Wildner, R.M. Blaese and J.C. Morris (1999) Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 59 410-413.
165. O. Wildner, R.M. Blaese and J.C. Morris (1999) Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan. Hum. Gene Ther. 10 2679-2687.
166. J. Tal (2000) Adeno-associated virus-based vectors in gene therapy. J. Biomed. Sci. 7 279-291.
167. R.L. Martuza (2000) Conditionally replicating herpes vectors for cancer therapy. J. Clin. Invest. 105 841-846.
168. G. Coukos, A. Makrigiannakis, E.H. Kang, D. Caparelli, I. Benjamin, L.R. Kaiser, S.C. Rubin, S.M. Albelda and K.L. Molnar-Kimber (1999) Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for intraperitoneal therapy of epithelial ovarian cancer. Clin. Cancer Res. 5 1523-1537.
169. M.W. Carroll and B. Moss (1997) Poxviruses as expression vectors. Curr. Opin. Biotechnol. 8 573-577.
170. D.M. Nettelbeck, V. Jérome and R. Müller (2000) Gene therapy: Designer promoters for tumour targeting. Trends Genet. 16 174-181.
171. D.L. Tait, P.S. Obermiller, A.R. Hatmaker, S. Redlin-Frazier and J.T. Holt (1999) Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. Clin. Cancer Res. 5 1708-1714.
172. J.T. Douglas, B.E. Rogers, M.E. Rosenfeld, S.I. Michael, M. Feng and D.T. Curiel (1996) Targeted gene delivery by tropismmodified adenoviral vectors. Nat. Biotechnol. 14 1574-1578.
173. I. Dmitriev, V. Krasnykh, C.R. Miller, M. Wang, E. Kashentseva, G. Mikheeva, N. Belousova and D.T. Curiel (1998) An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptorindependent cell entry mechanism. J. Virol. 72 9706-9713.
174. V. Krasnykh, I. Dmitriev, G. Mikheeva, C.R. Miller, N. Belousova and D.T. Curiel (1998) Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol. 72 1844-1852.
175. C. Rancourt, B.E. Rogers, B.A. Sosnowski, M. Wang, A. Piche, G.F. Pierce, R.D. Alvarez, G.P. Siegal, J.T. Douglas and D.T. Curiel (1998) Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. J. Clin. Cancer Res. 4 2455-2461.
176. T.J. Wickham, E. Tzeng, L.L. Shears 2nd, P.W. Roelvink, Y. Li, G.M. Lee, D.E. Brough, A. Lizonova and I. Kovesdi (1997) Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71 8221-8229.
177. T.J. Wickham, D.M. Segal, P.W. Roelvink, M.E. Carrion, A. Lizonova, G.M. Lee and I. Kovesdi (1996) Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol. 70 6831-6838.
178. T.J. Vanderkwaak, M. Wang, J. Gomez-Navarro, C. Rancourt, I. Dmitriev, V. Krasnykh, M. Barnes, G.P. Siegal, R. Alvarez and D.T. Curiel (1999) An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol. Oncol. 74 227-234.
179. J. Sudimack and R.J. Lee (2000) Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41 147-162.
180. M.A. Printz, A.M. Gonzalez, M. Cunningham, D.L. Gu, M. Ong, G.F. Pierce and S.L. Aukerman (2000) Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Hum. Gene Ther. 11 191-204.
181. K.D. Fisher, Y. Stallwood, N.K. Green, K. Ulbrich, V. Mautner and L.W. Seymour (2001) Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8 341-348.
182. J. Doukas, D.K. Hoganson, M. Ong, W. Ying, D.L. Lacey, A. Baird, G.F. Pierce and B.A. Sosnowski (1999) Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways. FASEB J 13 1459-1466.
183. P.N. Reynolds, M. Feng and D.T. Curiel (1999) Chimeric viral vectors—the best of both worlds? Mol. Med. Today 5 25-31.
184. C.M. Gorman, G.T. Merlino, M.C. Willingham, I. Pastan and B.H. Howard (1982) The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc. Natl. Acad. Sci. USA 79 6777-6781.
185. M. Boshart, F. Weber, G. Jahn, K.F.B. Dorsch-Hasler and W. Schaffner (1985) A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41 521-530.
186. M.K. Foecking and H. Hofstetter (1986) Powerful and versatile enhancer-promoter unit for mammalian expression vectors. Gene 45 101-105.
187. M.E. Rosenfeld, M. Feng, S.I. Michael, G.P. Siegal, R.D. Alvarez and D.T. Curiel (1995) Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin. Cancer Res. 1 1571-1580.
188. W. Walther and U. Stein (1996) Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting. J. Mol. Med. 74 379-392.
189. R.G. Vile, K. Sunassee and R.M. Diaz (1998) Strategies for achieving multiple layers of selectivity in gene therapy. Mol. Med. Today 4 84-92.
190. T. Osaki, Y. Tanio, I. Tachibana, S. Hosoe, T. Kumagai, I. Kawase, S. Oikawa and T. Kishimoto (1994) Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 54 5258-5261.
191. C.A. Richards, E.A. Austin and B.E. Huber (1995) Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy. Hum. Gene Ther. 6 881-893.
192. K.H. Lan, F. Kanai, Y. Shiratori, S. Okabe, Y. Yoshida, H. Wakimoto, H. Hamada, T. Tanaka, M. Ohashi and M. Omata (1996) Tumor-specific gene expression in carcinoembryonic antigen-producing gastric cancer cells using adenovirus vectors. Gastroenterology 111 1241-1251.
193. K.H. Lan, F. Kanai, Y. Shiratori, M. Ohashi, T. Tanaka, T. Okudaira, Y. Yoshida, H. Hamada and M. Omata (1997) In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res. 57 4279-4284.
194. B.E. Huber, C.A. Richards and T.A. Kremitsky (1991) Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA 88 8039-8043.
195. S. Kaneko, P. Hallenbeck, T. Kotani, H. Nakabayashi, G. McGarrity, T. Tamaoki, W.F. Anderson and Y.L. Chiang (1995) Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 55 5283-5287.
196. A. Ido, K. Nakata, Y. Kato, K. Nakao, K. Murata, M. Fujita, N. Ishii, T. Tamaoki, H. Shiku and S. Nagataki (1995) Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res. 55 3105-3109.
197. F. Kanai, K.H. Lan, Y. Shiratori, T. Tanaka, M. Ohashi, T. Okudaira, Y. Yoshida, H. Wakimoto, H. Hamada, H. Nakabayashi, T. Tamaoki and M. Omata (1997) In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 57 461-465.
198. R.G. Vile and I.R. Hart (1993) Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 53 3860-3864.
199. R.G. Vile and I.R. Hart (1993) In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53 962-967.
200. R.G. Vile, J.A. Nelson, S. Castleden, H. Chong and I.R. Hart (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54 6228-6234.
201. R.M. Diaz, T. Eisen, I.R. Hart and R.G. Vile (1998) Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J. Virol. 72 789-795.
202. W.M. Siders, P.J. Halloran and R.G. Fenton (1998) Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus. Cancer Gene Ther. 5 281-291.
203. Y. Manome, M. Abe, M.F. Hagen, H.A. Fine and D.W. Kufe (1994) Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res. 54 5408-5413.
204. M.W. Robertson 3rd, M. Wang, G.P. Siegal, M. Rosenfeld, R.S. Ashford 2nd, R.D. Alvarez, R.I. Garver and D.T. Curiel (1998) Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells. Cancer Gene Ther. 5 331-336.
205. K.B. Cleutjens, C.C. van Eekelen, H.A. van der Korput, A.O. Brinkmann and J. Trapman (1996) Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem. 271 6379-6388.
206. J. Dannull and A.S. Belldegrun (1997) Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. Br. J. Urol. 79(Suppl. 1), 97-103.
207. K.S. Koeneman, C. Kao, S.C. Ko, L. Yang, Y. Wada, D.F. Kallmes, J.Y. Gillenwater, H.E. Zhau, L.W. Chung and T.A. Gardner (2000) Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J. Urol. 18 102-110.
208. T. Kijima, T. Osaki, K. Nishino, T. Kumagai, T. Funakoshi, H. Goto, I. Tachibana, Y. Tanio and T. Kishimoto (1999) Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Res. 59 4906-4911.
209. A.K. Godwin, P.D. Miller, L.A. Getts, K. Jackson, G. Sonoda, K.J. Schray, J.R. Testa and T.C. Hamilton (1995) Retroviral-like sequences specifically expressed in the rat ovary detect genetic differences between normal and transformed rat ovarian surface epithelial cells. Endocrinology 136 4640-4649.
210. M. Selvakumaran, R. Bao, A.P. Crijns, D.C. Connolly, J.K. Weinstein and T.C. Hamilton (2001) Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res. 61 1291-1295.
211. J. Leavitt (1994) Discovery and characterization of two novel human cancer-related proteins using two-dimensional gel electrophoresis. Electrophoresis 15 345-357.
212. C.S. Lin, C.H. Chang and T. Huynh (1997) The murine L-plastin gene promoter: Identification and comparison with the human L-plastin gene promoter. DNA Cell Biol. 16 9-16.
213. T. Park, Z.P. Chen and J. Leavitt (1994) Activation of the leukocyte plastin gene occurs in most human cancer cells. Cancer Res. 54 1775-1781.
214. X.Y. Peng, J.H. Won, T. Rutherford, T. Fujii, D. Zelterman, G. Pizzorno, E. Sapi, J. Leavitt, B. Kacinski, R. Crystal, P. Schwartz and A. Deisseroth (2001) The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res. 61 4405-4413.
215. D.E. Hallahan, H.J. Mauceri, L.P. Seung, E.J. Dunphy, J.D. Wayne, N.N. Hanna, A. Toledano, S. Hellman, D.W. Kufe and R.R. Weichselbaum (1995) Spatial and temporal control of gene therapy using ionizing radiation. Nat. Med. 1 786-791.
216. L.P. Seung, H.J. Mauceri, M.A. Beckett, D.E. Hallahan, S. Hellman and R.R. Weichselbaum (1995) Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res. 55 5561-5565.
217. H.J. Mauceri, N.N. Hanna, J.D. Wayne, D.E. Hallahan, S. Hellman and R.R. Weichselbaum (1996) Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 56 4311-4314.
218. Y. Manome, T. Kunieda, P.Y. Wen, T. Koga, D.W. Kufe and T. Ohno (1998) Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: Activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum. Gene Ther. 9 1409-1417.
219. T. Joki, M. Nakamura and T. Ohno (1995) Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Hum. Gene Ther. 6 1507-1513.
220. Y. Kawashita, A. Ohtsuru, Y. Kaneda, Y. Nagayama, Y. Kawazoe, S. Eguchi, H. Kuroda, H. Fujioka, M. Ito, T. Kanematsu and S. Yamashita (1999) Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation. Hum. Gene Ther. 10 1509-1519.
221. W. Walther, J. Wendt and U. Stein (1997) Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. Gene Ther 4 544-552.
222. R.R. Weichselbaum, D.E. Hallahan, M.A. Beckett, H.J. Mauceri, H. Lee, V.P. Sukhatme and D.W. Kufe (1994) Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 54 4266-4269.
223. M.H. Jeng, C. Kao, L. Sivaraman, S. Krnacik, L.W.K. Chung, D. Medina, O.M. Conneely and B.W. O'Malley (1998) Reconstitution of estrogen-dependent transcriptional activation of an adenoviral target gene in selected regions of the rat mammary gland. Endocrinology 139 2916-2925.
224. T. Shibata, A.J. Giaccia and J.M. Brown (2000) Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther 7 493-498.
225. G.L. Semenza (2001) HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 13 167-171.
226. S. Nandi, R.C. Guzman and J. Yang (1995) Hormones and mammary carcinogenesis in mice, rats, and humans: A unifying hypothesis. Proc. Natl. Acad. Sci. USA 92 3650-3657.
227. R.S. Freedman, P.B. Saul, C.L. Edwards, C.J. Jolles, D.M. Gershenson, L.A. Jones, E.N. Atkinson and W.J. Dana (1986) Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study. Cancer Treat. Rep. 70 369-373.
228. D.G. Kieback, S.K. McCamant, M.F. Press, E.N. Atkinson, H.S. Gallager, C.L. Edwards, R.A. Hajek and L.A. Jones (1993) Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor. Cancer Res. 53 5188-5192.
229. J.D. Nash, R.F. Ozols, J.F. Smyth and T.C. Hamilton (1989) Estrogen and anti-estrogen effects on the groth of human epithelial ovarian cancer in vitro. Obstet. Gynecol. 73 1009-1016.
230. G.U. Dachs, A.V. Patterson, J.D. Firth, P.J. Ratcliffe, K.M. Townsend, I.J. Stratford and A.L. Harris (1997) Targeting gene expression to hypoxic tumor cells. Nat. Med. 3 515-520.
231. S. Agha-Mohammadi and M.T. Lotze (2000) Regulatable systems: Applications in gene therapy and replicating viruses. J. Clin. Invest. 105 1177-1183.
232. M. Gossen and H. Bujard (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89 5547-5551.
233. Y. Wang, F.J. DeMayo, S.Y. Tsai and B.W. O'Malley (1997) Ligand-inducible and liver-specific target gene expression in transgenic mice. Nat. Biotechnol. 15 239-243.
234. D. No, T.P. Yao and R.M. Evans (1996) Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. USA 93 3346-3351.
235. V.E. Allgood and E.M. Eastman (1997) Chimeric receptors as gene switches. Curr. Opin. Biotechnol. 8 474-479.
236. T. Clackson (1997) Controlling mammalian gene expression with small molecules. Curr. Opin. Chem. Biol. 1 210-218.
237. D.M. Harvey and C.T. Caskey (1998) Inducible control of gene expression: Prospects for gene therapy. Curr. Opin. Chem. Biol. 2 512-518.
238. E. Saez, D. No, A. West and R.M. Evans (1997) Inducible gene expression in mammalian cells and transgenic mice. Curr. Opin. Chem. Biotechnol. 8 608-616.
239. M.M. Burcin, G. Schiedner, S. Kochanek, S.Y. Tsai and B.W. O'Malley (1999) Adenovirus-mediated regulable target gene expression in vivo. Proc. Natl. Acad. Sci. USA 96 355-360.
240. M.L. Schmitz and P.A. Baeuerle (1991) The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO J. 10 3805-3817.
241. Y. Wang, B.W. O'Malley Jr., S.Y. Tsai and B.W. O'Malley (1994) A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. USA 91 8180-8184.
242. Y. Wang, J. Xu, T. Pierson, B.W. O'Malley and S.Y. Tsai (1997) Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator. Gene Ther. 4 432-441.
243. T. Hunter (1997) Oncoprotein networks. Cell 88 333-346.
244. C. Lengauer, K.W. Kinzler and B. Vogelstein (1998) Genetic instabilities in human cancers. Nature 396 643-649.
245. A.J. Levine (1997) p53, the cellular gatekeeper for growth and division. Cell 88 323-331.
246. R.A. DePinho (2000) The age of cancer. Nature 408 248-254.
247. K. Macleod (2000) Tumor suppressor genes. Curr. Opin. Genet. Dev. 10 81-93.
248. D. Malkin, F.P. Li, L.C. Strong, J.F. Fraumeni Jr., C.E. Nelson, D.H. Kim, J. Kassel, M.A. Gryka, F.Z. Bischoff, M.A. Tainsky, et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 1233-1238.
249. B.A. Werness, A.J. Levine and P.M. Howley (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248 76-79.
250. M. Scheffner, B.A. Werness, J.M. Huibregtse, A.J. Levine and P.M. Howley (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 1129-1236.
251. M. Scheffner, K. Munger, J.C. Byrne and P.M. Howley (1991) The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA 88 5523-5527.
252. A. Storey, M. Thomas, A. Kalita, C. Harword, D. Gardiol, F. Mantovani, J. Breuer, I.M. Leigh, G. Matlashewski and L. Banks (1998) Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature 393 229-234.
253. D.P. Lane (1992) Cancer. p53, guardian of the genome. Nature 358 15-16.
254. C.J. Sherr and J.D. Weber (2000) The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10 94-99.
255. K.H. Vousden and G.F. Vande Woude (2000) The ins and outs of p53. Nat. Cell Biol. 2 E178-E180.
256. B. Vogelstein, D. Lane and A.J. Levine (2000) Surfing the p53 network. Nature 408 307-310.
257. M. Hollstein, D. Sidransky, B. Vogelstein and C.C. Harris (1991) p53 mutations in human cancers. Science 253 49-53.
258. L.J. Ko and C. Prives (1996) p53: Puzzle and paradigm. Genes Dev. 10 1054-1072.
259. A.J. Giaccia and M.B. Kastan (1998) The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Dev. 12 2973-2983.
260. T. Rich, R.L. Allen and A.H. Wyllie (2000) Defying death after DNA damage. Nature 407 777-783.
261. K.H. Vousden (2000) p53: Death star. Cell 103 691-694.
262. J.A. Roth and R.J. Cristiano (1997) Gene therapy for cancer: What have we done and where are we going? J. Natl. Cancer Inst. 89 21-39.
263. L.L. Nielsen and D.C. Maneval (1998) P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther. 5 52-63.
264. J.T. Santoso, D.C. Tang, S.B. Lane, J. Hung, D.J. Reed, C.Y. Muller, D.P. Carbone, J.A. Lucci 3rd, D.S. Miller and J.M. Mathis (1995) Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol. Oncol. 59 171-178.
265. K. Mujoo, D.C. Maneval, S.C. Anderson and J.U. Gutterman (1996) Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 12 1617-1623.
266. L.L. Nielsen, P. Lipari, J. Dell, M. Gurnani and G. Hajian (1998) Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. 4 835-846.
267. V.E. Von Gruenigen, J.T. Santoso, R.L. Coleman, C.Y. Muller, D.S. Miller and J.M. Mathis (1998) In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer. Gynecol. Oncol. 69 197-204.
268. J. Kim, E.S. Hwang, J.S. Kim, E.H. You, S.H. Lee and J.H. Lee (1999) Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse. Cancer Gene Ther. 6 172-178.
269. J.K. Wolf, G.B. Mills, L. Bazzet, R.C. Bast Jr., J.A. Roth and D.M. Gershenson (1999) Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol. Oncol. 75 261-266.
270. V.E. Von Grueningen, J.D. O'Boyle, R.L. Coleman, D. Wilson, D.S. Miller and J.M. Mathis (1999) Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer. Int. J. Gynecol. Cancer 9 365-372.
271. Q. Wu, R. Kreienberg and I.B. Runnebaum (2000) Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro. J. Cancer Res. Clin. Oncol. 126 139-144.
272. K. Mujoo, L. Zhang, J. Klostergaard and N.J. Donato (2000) Emergence of cisplatin-resistant cells from the OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity, and increased apoptotic sensitivity to p53 gene replacement. Int. J. Gynecol. Cancer 10 105-114.
273. D.L. Barnard (2000) Technology evaluation: Sch-58500, Canji. Curr. Opin. Mol. Ther. 2 586-592.
274. A.G. Eliopoulos, D.J. Kerr, J. Herod, L. Hodgkins, S. Krajewski, J.C. Reed and L.S. Young (1995) The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bc1-2. Oncogene 11 1217-1218.
275. F. Vikhanskaya, M. D;Incalci and M. Broggini (1995) Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. Int. J. Cancer 61 397-401.
276. P.A. Vasey, N.A. Jones, S. Jenkins, C. Dive and R. Brown (1996) Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol. Pharmacol. 50 1536-1540.
277. W.M. Gallagher, M. Cairney, B. Schott, I.B. Roninson and R. Brown (1997) Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 14 185-193.
278. M. Ashcroft and K.H. Vousden (1999) Regulation of p53 stability. Oncogene 18 7637-7643.
279. P.D. Adams and W.G. Kaelin Jr. (1998) Negative control elements of the cell cycle in human tumors. Curr. Opin. Cell Biol. 10 791-797.
280. N.E. Sharpless and R.A. DePinho (1999) The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9 22-30.
281. D.A. Alcorta, Y. Xiong, D. Phelps, G. Hannon, D. Beach and J.C. Barrett (1996) Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. USA 93 13742-13747.
282. C.Y. Dai and G.H. Enders (2000) p16 INK4a can initiate an autonomous senescence program. Oncogene 19 1613-1622.
283. M. Schreiber, W.J. Muller, G. Singh and F.L. Graham (1999) Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene 18 1663-1676.
284. S.C. Modesitt, P. Ramirez, Z. Zu, D. Bodurka-Bevers, D. Gershenson and J.K. Wolf (2001) In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin. Cancer Res. 7 1765-1772.
285. M.E. Murphy (2001) The battle between tumor suppressors: Is gene therapy using p16(INK4a) more efficacious than p53 for treatment of ovarian carcinoma? Clin. Cancer Res. 7 1487-1489.
286. P.L. Welcsh, K.N. Owens and M.C. King (2000) Insights into the functions of BRCA1 and BRCA2. TIG 16 69-74.
287. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal P.A., Harshman, K., Tavtigian S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66–71.
288. R. Scully and D.M. Livingston (2000) In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408 429-432.
289. K. Somasundaram, H. Zhang, Y.X. Zeng, Y. Houvras, Y. Peng, G.S. Wu, J.D. Licht, B.L. Weber and W.S. El-Deiry (1997) Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 389 187-190.
290. H. Zhang, K. Somasundaram, Y. Peng, H. Tian, D. Bi, B.L. Weber and W.S. El-Deiry (1998) BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16 1713-1721.
291. N. Shao, Y.L. Chai, E. Shyam, P. Reddy and V.N. Rao (1996) Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene 13 1-7.
292. J.T. Holt, M.E. Thompson, C. Szabo, C. Robinson-Benion, C.L. Arteaga, M.C. King and R.A. Jensen (1996) Growth retardation and tumour inhibition by BRCA1. Nat. Genet. 12 298-302.
293. D.L. Tait, P.S. Obermiller and J.T. Holt (2000) Preclinical studies of a new generation retroviral vector for ovarian cancer BRCA1 gene therapy. Gynecol. Oncol. 79 471-476.
294. J.C. Reed (1999) Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol. 11 68-75.
295. F. Bunz (2001) Cell death and cancer therapy. Curr. Opin. Pharmacol. 1 337-341.
296. P.H. Krammer (2000) CD95's deadly mission in the immune system. Nature 407 789-795.
297. M. Bennett, K. Macdonald, S.W. Chan, J.P. Luzio, R. Simari and P. Weissberg (1988) Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis. Science 282 290-293.
298. P.J. Morin, B. Vogelstein and K.W. Kinzler (1996) Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. USA 93 7950-7954.
299. Z.G. Wang, D. Ruggero, S. Ronchetti, S. Zhong, M. Gaboli, R. Rivi and P.P. Pandolfi (1998) PML is essential for multiple apoptotic pathways. Nat. Genet. 20 266-272.
300. Y.T. Tai, S. Lee, E. Niloff, C. Weisman, T. Strobel and S.A. Cannistra (1998) BAX protein expression and clinical outcome in epithelial ovarian cancer. J. Clin. Oncol. 16 2583-2590.
301. T. Strobel, L. Swanson, S. Korsmeyer and S.A. Cannistra (1996) BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc. Natl. Acad. Sci. USA 93 14094-14099.
302. T. Strobel, L. Swanson, S. Korsmeyer and S.A. Cannistra (1997) Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells. Oncogene 14 2753-2758.
303. Y.T. Tai, T. Strobel, D. Kufe and S.A. Cannistra (1999) In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX Gene. Cancer Res. 59 2121-2126.
304. P.P. Di Fiore, J.H. Pierce, M.H. Kraus, O. Segatto, C.R. King and S.A. Aaronson (2001) erbB-2 is a potent oncogene when over-expressed in NIH/3T3 cells. Science 237 178-182.
305. N. Prenzel, O.M. Fischer, S. Streit, S. Hart and A. Ullrich (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 8 11-31.
306. Y. Yarden and M.X. Sliwkowski (2001) Untangling the ErbB signalling networks. Nat. Rev. Mol. Cell Biol. 2 127-137.
307. B.M. Fendly, M. Winget, R.M. Hudziak, M.T. Lipari, M.A. Napier and A. Ullrich (1990) Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50 1550-1558.
308. R.D. Alvarez and D.T. Curiel (1997) A phase 1 study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (hsv-tk) gene and intraveneous ganciclovir for previously treated ovarian and extraovarian cancer patients. Hum. Gene Ther. 8 597-613.
309. F.H. Igney, C.K. Behrens and P.H. Krammer (2000) Tumor counterattack—concept and reality. Eur. J. Immunol. 30 725-731.
310. S.A. Rosenberg (2001) Progress in human tumour immunology and immunotherapy. Nature 411 380-384.
311. R.M. Dallal and M.T. Lotze (2000) The dendritic cell and human cancer vaccines. Curr. Opin. Immunol. 12 583-588.
312. I. Melero, G. Mazzolini, I. Narvaiza, C. Qian, L. Chen and J. Prieto (2001) IL-12 gene therapy for cancer: In synergy with other immunotherapies. Trends Immunol. 22 113-115.
313. A.N. Houghton, J.S. Gold and N.E. Blachere (2001) Immunity against cancer: Lessons learned from melanoma. Curr. Opin. Immunol. 13 134-140.
314. T. Boon and L.J. Old (1997) Cancer tumor antigens. Curr. Opin. Immunol. 9 681-683.
315. R. Sanches, M. Kuiper, F. Penault-Llorca, B. Aunoble, C. D'Incan and Y.J. Bignon (2000) Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: Implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy. Cancer Gene Ther. 7 707-720.
316. J. Gong, N. Nikrui, D. Chen, S. Koido, Z. Wu, Y. Tanaka, S. Cannistra, D. Avigan and D. Kufe (2000) Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. 165 1705-1711.
317. S.M. Freeman (2000) Suicide gene therapy. Adv. Exp. Med. Biol. 465 411-422.
318. O. Greco and G.U. Dachs (2001) Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives. J. Cell Physiol. 187 22-36.
319. I. Niculescu-Duvaz, R. Spooner, R. Marais and C.J. Springer (1998) Gene-directed enzyme prodrug therapy. Bioconjug Chem. 9 4-22.
320. J.A. Bridgewater, C.J. Springer, R.J. Knox, N.P. Minton, N.P. Michael and M.K. Collins (1995) Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A 2362-2370.
321. T. Tamiya, Y. Ono, M.X. Wei, P.J. Mroz, F.L. Moolten and E.A. Chiocca (1996) Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. Cancer Gene Ther. 3 155-162.
322. R. Marais, R.A. Spooner, Y. Light, J. Martin and C.J. Springer (1996) Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56 4735-4742.
323. M.S. Dilber, M.R. Abedi, B. Christensson, B. Bjorkstrand, G.M. Kidder, C.C. Naus, G. Gahrton and C.I. Smith (1997) Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. 57 1523-1528.
324. S. Gagandeep, R. Brew, B. Green, S.E. Christmas, D. Klatzmann, G.J. Poston and A.R. Kinsella (1996) Prodrug-activated gene therapy: Involvement of an immunological component in the “bystander effect”. Cancer Gene Ther. 3 83-88.
325. J. Pavlovic, M. Nawrath, R. Tu, T. Heinicke and K. Moelling (1996) Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V). Gene Ther. 3 635-643.
326. R. Ramesh, A.J. Marrogi, A. Munshi, C.N. Abboud and S.M. Freeman (1996) In vivo analysis of the “bystander effect”: A cytokine cascade. Exp. Hematol. 24 829-838.
327. R.L. Touraine, N. Vahanian, W.J. Ramsey and R.M. Blaese (1998) Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum. Gene Ther. 9 2385-2391.
328. A. Hasenburg, X.W. Tong, A. Rojas-Martinez, C. Nyberg-Hoffman, C.C. Kieback, A.L. Kaplan, R.H. Kaufman, I. Ramzy, E. Aguilar-Cordova and D.G. Kieback (1999) Thymidine kinase (TK) gene therapy of solid tumors: Valacyclovir facilitates outpatient treatment. Anticancer Res. 19 2163-2165.
329. A. Hasenburg, X.W. Tong, A. Rojas-Martinez, C. Nyberg-Hoffman, C.C. Kieback, A. Kaplan, R.H. Kaufman, I. Ramzy, E. Aguilar-Cordova and D.G. Kieback (2000) Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther. 7 839-852.
330. R.D. Alvarez, J. Gomez-Navarro, M. Wang, M.N. Barnes, T.V. Strong, R.B. Arani, W. Arafat, J.V. Hughes, G.P. Siegal and D.T. Curiel (2000) Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol. Ther. 2 524-530.
331. M.E. Black, T.G. Newcomb, H.M. Wilson and L.A. Loeb (1996) Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc. Natl. Acad. Sci. USA 93 3525-3529.
332. C. Beltinger, S. Fulda, T. Kammertoens, E. Meyer, W. Uckert and K.M. Debatin (1999) Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc. Natl. Acad. Sci. USA 96 8699-8704.
333. A. Melcher, S. Todryk, N. Hardwick, M. Ford, M. Jacobson and R.G. Vile (1998) Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 4 581-587.
334. R. Thust, M. Tomicic, R. Klocking, N. Voutilainen, P. Wutzler and B. Kaina (2000) Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: Implications for gene therapeutic approaches. Cancer Gene Ther. 7 107-117.
335. R.G. Vile, S. Castleden, J. Marshall, R. Camplejohn, C. Upton and H. Chong (1997) Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer 71 267-274.
336. S.J. Wei, Y. Chao, Y.M. Hung, W.C. Lin, D.M. Yang, Y.L. Shih, L.Y. Chang, J. Whang-Peng and W.K. Yang (1998) S- and G2-phase cell cycle arrests and apoptosis induced by ganciclovir in murine melanoma cells transduced with herpes simplex virus thymidine kinase. Exp. Cell Res. 241 66-75.
337. S.M. Freeman, R. Ramesh and A.J. Marrogi (1997) Immune system in suicide-gene therapy. Lancet 394 2-3.
338. S.H. Chen, X.H.L. Chen, Y. Wang, K.I. Kosai, M.J. Finegold, S.S. Rich and S.L.C. Woo (1995) Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. Natl. Acad. Sci. 92 2577-2581.
339. C.T. Freund, M.A. Sutton, T. Dang, C.F. Contant, D. Rowley and S.P. Lerner (2000) Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer. Anticancer Res. 20 1359-1365.
340. K. Behbakht, I. Benjamin, H.-C. Chiu, S.L. Eck, P.G. Van Deerlin, S.C. Rubin and J. Boyd (1996) Adenovirus-mediated gene therapy of ovarian cancer in a mouse model. Am. J. Obstet. Gynecol. 175 1260-1265.
341. X.W. Tong, D.G. Engehausen, C.T.F. Freund, I. Agoulnik, M.K. Oehler, T.E. Kim, A. Hasenburg, Z. Guo, C.F. Contant, S.L.C. Woo and D.G. Kieback (1999) Comparison of long-term survival of cytomegalovirus promoter versus rous sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer. Hybridoma 18 93-97.
342. X.W. Tong, A. Block, S.H. Chen, C.F. Contant, I. Agoulnik, K. Blankenburg, R.H. Kaufman, S.L.C. Woo and D.G. Kieback (1996) In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol. Oncol. 61 175-179.
343. W. Hassan, M.A. Sanford, S.L. Woo, S.H. Chen and S.J. Hall (2000) Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer. World J. Urol. 18 130-135.
344. S.A. Rosenberg, R.M. Blaese, M.K. Brenner, A.B. Deisseroth, F.D. Ledley, M.T. Lotze, J.M. Wilson, G.J. Nabel, K. Cornetta, J.S. Economou, S.M. Freeman, S.R. Riddell, M. Brenner, E. Oldfield, B. Gansbacher, C. Dunbar, R.E. Walker, F.G. Schuening, J.A. Roth, R.G. Crystal, M.J. Welsh, K. Culver, H.E. Heslop, J. Simons, R.W. Wilmott, R.C. Boucher, H.F. Siegler, J.A. Barranger, S. Karlsson, D. Kohn, J.E. Galpin, C. Raffel, C. Hesdorffer, J. Ilan, P. Cassileth, J. O'Shaughnessy, L.E. Kun, T.K. Das, F. Wong-Staal, R.E. Sobol, R. Haubrich, M. Sznol, J. Rubin, E.J. Sorcher, J. Rosenblatt, R. Walker, K. Brigham, N. Vogelzang, E. Hersh, D. Curiel, C.H. Evans, R. Freedman, J. Liu, J. Simons, T.R. Flotte, J. Holt, H.K. Lyerly, C.B. Whitley, J.M. Isner and S.L. Eck (2000) Human gene marker/therapy clinical protocols. Hum. Gene ther. 11 919-979.
345. M. Bouvet, B. Fang, S. Ekmekcioglu, L. Ji, C.D. Bucana, K. Hamada, E.A. Grimm and J.A. Roth (1998) Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther. 5 188-195.
346. D.M. Nguyen, F.R. Spitz, N. Yen, R.J. Cristiano and J.A. Roth (1996) Gene therapy for lung cancer: Enhancement of tumor, suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J. Thorac. Cardiovasc. Surg. 112 1372-1377.
347. X.W. Tong, D.H. Shine, I. Agoulnik, C.T.F. Freund, A. Hasenburg, E. Aguilar-Cordova, S.L.C. Woo and D.G. Kieback (1998) Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents. Anticancer Res. 18 3421-3426.
348. T.-C. Chou (1991) The median-effect principle and the combination index for quantitation of synergism and antagonism. T.C. Chou, D.C. Rideout (Eds) Synergism and Antagonism in Chemotherapy San Diego CA: Academic Press 61-102.
349. T.C. Chou and P. Talalay (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regulat. 22 27-55.
350. A.F. Wahl, K.L. Donaldson, C. Fairchild, F.Y. Lee, S.A. Foster, G.W. Demers and D.A. Galloway (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2 72-79.
351. R.A. Gjerset, S.T. Turla, R.E. Sobol, J.J. Scalise, D. Mercola, H. Collins and P.J. Hopkins (1995) Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol. Carcinog. 14 275-285.
352. B. Yang, J.R. Eshleman, N.A. Berger and S.D. Markowitz (1996) Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin. Cancer Res. 2 1649-1657.
353. M.V. Blagosklonny and W.S. El-Deiry (1996) In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int. J. Cancer 67 386-392.
354. F.R. Spitz, D. Nguyen, J.M. Skibber, R.E. Meyn, R.J. Cristiano and J.A. Roth (1996) Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin. Cancer Res. 2 1665-1671.
355. D. Gallardo, K.E. Drazan and W.H. McBride (1996) Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res. 56 4891-4893.
356. H. Romig and A. Richter (1990) Expression of the type I DNA topoisomerase gene in adenovirus-5 infected human cells. Nucleic Acids Res. 18 801-808.
357. J.M. Wilson (1997) Adenoviruses as gene-delivery vehicles. N. Engl. J. Med. 334 1185-1187.
358. K.M. Hui, P.T. Ang, L. Huang and S.K. Tay (1997) Phase 1 study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. Gene Ther. 4 783-790.
359. R.D. Alvarez and D.T. Curiel (1997) A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients. Hum. Gene Ther. 8 229-242.
360. A. Hasenburg, X.W. Tong, D.C. Fischer, A. Rojas-Martinez, C. Nyberg-Hoffman, A.L. Kaplan, R.H. Kaufman, I. Ramzy, E. Aguilar-Cordova and D.G. Kieback (2001) Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol. Oncol. 83 549-554.
361. A. Hasenburg, D.C. Fischer, X.W. Tong, A. Rojas-Martinez, R.H. Kaufman, I. Ramzy, P. Kohlberger, M. Orlowska-Volk, E. Aguilar-Cordova and D.G. Kieback (2002) Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: Expression of coxsackie-adenovirus receptor and integrins alphav-beta3 and alphavbeta5. J. Soc. Gynecol. Investig. 9 174-180.
362. A. Hasenburg, D.C. Fischer, X.W. Tong, A. Rojas-Martinez, C. Nyberg-Hoffman, M. Orlowska-Volk, P. Kohlberger, R.H. Kaufman, I. Ramzy, E. Aguilar-Cordova and D.G. Kieback (2002) Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer. Int. J. Gynecol. Cancer 12 66-73.